RAPT Therapeutics Inc 2025年季度报告

SECURITIES AND EXCHANGE COMMISSION Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during thepreceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of RegulationS-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerginggrowth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2of the Exchange Act. PART I. FINANCIAL INFORMATION Item 1.Financial Statements (Unaudited)Condensed Balance Sheets as of March 31, 2025 and December 31, 2024Condensed Statements of Operations and Comprehensive Loss for the Three-Months Ended March 31, 2025and 2024Condensed Statements of Stockholders’ Equity for the Three-Months Ended March 31, 2025 and 2024Condensed Statements of Cash Flows for the Three-Months Ended March 31, 2025 and 2024 PART II. OTHER INFORMATION Item 1.Legal ProceedingsItem 1A.Risk FactorsItem 2.Unregistered Sales of Equity Securities and Use of ProceedsItem 3.Defaults Upon Senior SecuritiesItem 4.Mine Safety DisclosuresItem 5.Other InformationItem 6.Exhibits This Quarterly Report on Form 10-Q includes trademarks, service marks and trade names owned by us or other companies. Alltrademarks, service marks and trade names included in this Quarterly Report on Form 10-Q are the property of their respective RAPT THERAPEUTICS, INC.CONDENSED BALANCE SHEETS RAPT THERAPEUTICS, INC.NOTES TO CONDENSEDFINANCIAL STATEMENTS 1. Organization Description of the Business RAPT Therapeutics, Inc. (“RAPT” or the “Company”) is a clinical-stage immunology-based biopharmaceutical companyfocused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunologicaldiseases. The Company's lead drug candidate, RPT904, is a half-life extended monoclonal antibody designed to bind free humanimmunoglobulin E (“IgE”), a key driver of several allergic diseases. The Company’s oncology drug candidate, tivumecirnon, is anoral small-molecule C-C motif chemokine receptor 4 (“CCR4”) antagonist designed to selectively inhibit the migration ofimmunosuppressive regulatory T cells into tumors.In November 2024, the Company ceased development of zelnecirnon, its small Liquidity and Management Plans The accompanying condensed financial statements have been prepared assuming that the Company will continue as a goingconcern. Since inception, the Company has incurred net losses and negative cash flows from operations. During the three monthsended March 31, 2025, the Company incurred a net loss of $17.2million and used $52.5million of cash in operations and capital The Company plans to continue to incur substantial costs in order to conduct research and development activities, andadditional capital will be needed to undertake these activities. The Company intends to raise such capital through the issuance ofadditional equity, borrowings or strategic alliances with other companies. However, if such arrangements are not available atadequate levels or on acceptable terms, the Company would be required to significantly reduce operating expenses and delay or 2. Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally acceptedaccounting principles (“U.S. GAAP”) for interim financial information and pursuant to Article 10 of Regulation S‑X of theSecurities Act of 1933, as amended (the “Securities Act”). Accordingly, they do not include all of the information and notesrequired by U.S. GAAP for complete financial statements. These unaudited condensed financial statements include only normaland recurring adjustments that the Company believes are necessary to fairly state the Company’s financial position and the resultsof its operations and cash flows. Interim-period results are not necessarily indicative of results of operations or cash flows for a fullyear or any subsequent interim period. The condensed balance sheet as of December 31, 2024 has been derived from the audited Segments Operating segments are defined as components of an entity for which separate financial information is available and that areregularly reviewed by the chief operating decision maker (“CODM”) in deciding how to allocate resources to an individual The CODM assesses performance fo